The short version
Just 3 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Veklury
remdesivir · REMDESIVIR 100 mg/1 · Injection, Powder, Lyophilized, For Solution · Intravenous · Gilead Sciences, Inc.
NDC 61958-2901-02 · 1 VIAL, SINGLE-DOSE in 1 CARTON / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-DOSE · NDA · View full market →
One drug, every price
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
ⓘ How this was built
Data sources
- CMS NADAC (pharmacy acquisition, weekly)
- CMS Part B ASP quarterly payment limits
- CMS Maximum Fair Prices (IRA negotiated, NDC-level)
- Medicare Part D Spending by Drug (data.cms.gov, name-matched)
- VA FSS / Big4 federal contract prices (va.gov, twice monthly)
- ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
- California SB-17 WAC filings (list price, per package)
Method
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
- Medicare Part B pays (ASP+6%)$7.51per billing unit (1 MG)HCPCS J0248 · Jul 1, 2026
- Part D plans paid (avg)$208.57per dosage unitgross, before rebates — matched by drug name · 2024
- Federal ceiling (Big4)$448.50per unitGilead Sciences, Inc. · Jan 1, 2026
- List price (WAC, as filed)$708.63per packageGilead Sciences, Inc. · Jan 1, 2026
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$708.63
Reported to Texas DSHS · 2026 annual filing · Gilead Sciences, Inc.
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Medicare Part B (ASP)
Payment limit per 1 MG
$7.511
HCPCS J0248 · Jul 1, 2026 quarter · typically ASP + 6%
Medicaid spend (2025)
$640,964
1,146 prescriptions paid by Medicaid nationally · all Medicaid spend →
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Is this a "specialty" drug?
There's no legal definition — it meets 2 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $1,305.22 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- NDA214787
- TE code
- —
- Approval date
- Oct 22, 2020
- Patents / exclusivity
- 58 patents, 6 exclusivities
| Type | Number / code | Expires |
|---|---|---|
| exclusivity | PED | Jan 13, 2027 |
| exclusivity | PED | Jan 13, 2027 |
| exclusivity | M-301 | Jul 13, 2026 |
| exclusivity | M-301 | Jul 13, 2026 |
| exclusivity | NCE | Oct 22, 2025 |
| exclusivity | NCE | Oct 22, 2025 |
| patent | 11491169*PED | Nov 28, 2041 |
| patent | 11975012*PED | Nov 28, 2041 |
| patent | 11975012*PED | Nov 28, 2041 |
| patent | 11903953*PED | Nov 28, 2041 |
| patent | 11903953*PED | Nov 28, 2041 |
| patent | 11491169*PED | Nov 28, 2041 |
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
- Class I · TerminatedSep 19, 2024Gilead Sciences, Inc. — Presence of Particulate Matter: Presence of glass particle.
- Class I · TerminatedDec 3, 2021Gilead Sciences, Inc. — Presence of Particulate Matter: investigation into a customer complaint confirmed the presence of glass particulates.
Manufacturers of remdesivir (Injection, Powder, Lyophilized, For Solution)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Gilead Sciences, Inc. | REMDESIVIR 100 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Hospira, Inc. | REMDESIVIR 100 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Patheon Italia S.p.A. | REMDESIVIR 100 ug/30mL | Jul 15, 2026 | Aug 26, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Veklury — NDC 61958-2901-02," retrieved September 3, 2026, https://drugdashboards.com/drug/61958290102.
Free to cite with attribution — see how the data is put together.